Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market
Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate
Medicus Pharma Showcases Strong Phase 2 SkinJect Data Ahead of Fireside Chat
Medicus Pharma Highlights Strong Phase 2 SkinJect Results in Basal Cell Carcinoma
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd.